Results 1 to 10 of about 21,493 (144)

Impact of ileostomy creation on apixaban plasma concentrations: a retrospective case-series [PDF]

Annals of Saudi Medicine
BACKGROUND: Apixaban is a direct-acting oral anticoagulant indicated for stroke and systemic embolism prevention in atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE).
Hakeam A. Hakeam, Sandra McGrath, Ghader Alrebeh, Abdullah F. Alrebdi   +3 more
doaj   +2 more sources

Thrombin generation in HeartMate 3 patients on apixaban and vitamin K antagonists: Variability limits clinical applicability [PDF]

JHLT Open
Apixaban is increasingly replacing vitamin K antagonists (VKAs) during HeartMate 3 (HM3) left ventricular assist device support, but its pharmacodynamics in this setting remain poorly understood.
Charlotte J. Van Edom, MD, Walter Droogné, MD, Steven Jacobs, MD, PhD, Marc Jacquemin, MD PhD, Christine Van Laer, PhD, Joeri Van Puyvelde, MD, PhD, Dirk Vlasselaers, MD, PhD, Katrien Vandersmissen, Thomas Vanassche, MD, PhD, Bart Meyns, MD, PhD   +9 more
doaj   +2 more sources

Meta-análisis: Eficacia y seguridad de apixabán frente a warfarina en pacientes con fibrilación auricular para profilaxis de eventos cardiovasculares adversos

Cedamaz, 2022
Los pacientes con fibrilación auricular (FA) requieren terapia anticoagulante para prevenir eventos cardiovasculares adversos. Un fármaco muy empleado es warfarina con beneficios variables e inconsistentes y mayor riesgo de hemorragia.
Mariela Alexandra Idrovo Vallejo, Paula Blandin-Lituma   +1 more
doaj   +1 more source

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs

Frontiers in Veterinary Science, 2021
Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans.
Noelle D. Herrera, Ingvild Birschmann, Monika Wolny, Mark G. Papich, Marjory B. Brooks, Robert Goggs   +5 more
doaj   +1 more source

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. [PDF]

PLoS ONE, 2018
Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin.
Xiaoyan Li, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y H Lip, Steve Deitelzweig   +11 more
doaj   +1 more source

Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation

Scientific Reports, 2021
In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban variability in patients with atrial fibrillation and correlated these results with clinical outcome.
Alenka Mavri, Nina Vene, Mojca Božič-Mijovski, Marko Miklič, Lisbeth Söderblom, Anton Pohanka, Rickard E. Malmström, Jovan Antovic   +7 more
doaj   +1 more source

Análisis costo-efectividad de Apixaban versus Enoxaparina en pacientes sometidos a reemplazo total de cadera o rodilla en Colombia

Revista Colombiana de Ortopedia y Traumatología, 2016
Introducción: El artículo trata de estimar la rentabilidad del apixabán frente a la enoxaparina para prevenir la tromboembolia venosa (TEV) en pacientes intervenidos de reemplazo total de cadera (THR) o reemplazo total de rodilla (TKR) en Colombia ...
Jaime E. Ordóñez, Arlex U. Palacios
doaj   +1 more source

Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades

Biociencias, 2017
La tromboembolia representa una importante causa de morbimortalidad, siendo la anticoagulación el pilar del tratamiento. Los anticoagulantes orales directos, constituyen una opción que supera algunos de los inconvenientes con warfarina, como la ...
Irene González Aguirre
doaj   +1 more source

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. [PDF]

PLoS ONE, 2012
BACKGROUND: Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of ...
Soyon Lee, Rachel Mullin, Jon Blazawski, Craig I Coleman   +3 more
doaj   +1 more source

Nuevos anticoagulantes orales en pacientes con enfermedad renal crónica [PDF]

, 2017
RESUMEN: Los pacientes con enfermedad renal crónica (ERC) tienen tendencias hemorrágicas y trombóticas, por lo que la indicación de anticoagulación ante la aparición de fibrilación auricular (FA) es compleja.
Aguilar, Ansell, Belmar, Camm, Castillo, Chan, Connolly, Connolly, Diener, Douxfils, Easton, Eckardt, Expósito, Ferreira, Findlay, Fu, Gallagher, Giugliano, Granger, Hankey, Hart, January, January, Koudstaal, Krüger, Lin, Lutz, Miller, Morimoto, Murray, Olesen, Pancholy, Patel, Pisters, Pollack, Reinecke, Ruff, Schneeweiss, Soliman, Vázquez, Winkelmayer, Wittkowsky, Wizemann   +42 more
core   +3 more sources